Natalia Fabisiak

lek.

Specjalizacja

Choroby wewnętrzne - w trakcie

Publikacje naukowe

1.Fabisiak N., Fabisiak A, Chmielowiec-Korzeniowska A, Tymczyna L, Kamysz W, Kordek R, Bauer M, Kamysz E, Fichna J. Anti-inflammatory and antibacterial effects of human ca-thelicidin active fragment KR-12 in the mouse models of colitis: a novel potential therapy of inflammatory bowel diseases. Pharmacol Rep. 2021 Feb;73(1):163-171. doi: 10.1007/s43440-020-00190-3.
2.Fabisiak A., Fabisiak N., Mokrowiecka A., Malecka-Panas E., Jacenik D., Kordek R., Zie-lińska M., Kieć-Kononowicz K., Fichna J. Novel selective agonist of GPR18, PSB-KK-1415 exerts potent anti-inflammatory and anti-nociceptive activities in animal models of intestinal inflammation and inflammatory pain. Neurogastroenterol Motil. 2021 Mar;33(3):e14003. doi: 10.1111/nmo.14003.
3.Fabisiak N., Gąsiorowska A. Znaczenie kliniczne zespołów chylomikronemii w patogenezie i przebiegu ostrego zapalenia trzustki. Gastroenterologia praktyczna, 2020; 49 (4): 25-32
3.Fabisiak N., Gąsiorowska A. Znaczenie kliniczne zespołów chylomikronemii w patogenezie i przebiegu ostrego zapalenia trzustki. Gastroenterologia praktyczna, 2020; 49 (4): 25-32 4.Fabisiak A., Włodarczyk M., Fabisiak N., Storr M., Fichna J.: Gastrointestinal Adverse Events of Cannabinoid 1 Receptor Inverse Agonists Suggest Their Potential Use in Irritable Bowel Syndrome With Constipation: A Systematic Review and Meta-Analysis. J Gastroin-testin Liver Dis. 2019 Dec 9;28(4):473-481. doi: 10.15403/jgld-265.
5.Párniczky A, Lantos T, Tóth EM, Szakács Z, (...), Małecka-Panas E, Zatorski H, Gasiorow-ska A, Fabisiak N., (...), Sandblom G, Kacar S, Baltatzis M, Varabei AV, Yeshy V, Choo-klin S, Kozachenko A, Veligotsky N, Hegyi P; Hungarian Pancreatic Study Group. Antibio-tic therapy in acute pancreatitis: From global overuse to evidence based recommendations. Pancreatology. 2019 Jun;19(4):488-499. doi: 10.1016/j.pan.2019.04.003. Epub 2019 Apr 19. PMID: 31068256
6.Fabisiak A., Bartoszek A., Kardas G., Fabisiak N., Fichna J. Possible application of trefoil factor family peptides in gastroesophageal reflux and Barrett's esophagus. Peptides. 2019 May; 115:27-31. doi: 10.1016/j.peptides.2019.02.007
7.Fabisiak N., Fabisiak A., Małecka-Panas E., Gąsiorowska A. Acute pancreatitis – epidemio-logy, etiology, procedures and treatment: a retrospective cohort study, Post N Med 2018; XXXI(2A): 22-28
8.Fabisiak N., Fabisiak A., Watala C., Fichna J. Fat-soluble Vitamin Deficiencies and Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2017 Aug 30
9.Fabisiak A., Włodarczyk K., Fabisiak N., Storr M., Fichna J. Targeting Histamine Receptors in Irritable Bowel Syndrome: A Critical Appraisal. J Neurogastroenterol Motil. 2017 May 27
10.Fabisiak N. Clinical Features. In book: Introduction to Gastrointestinal Diseases Vol. 1, pp.103-112. Springer 2016.
11.Fabisiak A., Murawska N., Fichna J. LL-37: cathelicidin-related antimicrobial peptide with pleiotropic activity. Pharmacol Rep. 2016 Aug;68(4):802-8
12.Murawska N., Fabisiak A., Fichna J. Anemia of chronic disease and iron deficiency anemia in inflammatory bowel diseases: pathophysiology, diagnosis, and treatment. Inflamm Bowel Dis. 2016 May;22(5):1198-208
13.Fabisiak A. , Murawska N. , Mokrowiecka A. , Małecka-Panas E. , Fichna J. Clinical as-sessment of inflammatory bowel disease activity: a critical overview. Journal of Medical Science. 2015;2(84):116-128
14.Salaga M., Polepally P., Zielinska M., Marynowski M., Fabisiak A., Muraw-ska N., Sobczak K., Sacharczuk M., Do Rego JC., Roth B., Zjawiony J., Fichna J. : Salvinorin A analogs PR-37 and PR-38 attenuate compound 48/80-induced itch responses in mice. Br J Pharmacol. 2015 Sep;172(17):4331-41
15.Fabisiak A., Murawska N., Fichna J. Comment on "Intestinal inflammation modulates expression of the iron-regulating hormone hepcidin depending on erythropoietic activity and the commensal microbiota". J Immunol. 2014 Dec 15;193(12):5763. doi: 10.4049/jimmunol.1402516.
16.Sobczak M., Fabisiak A., Murawska N., Wesołowska E., Wierzbicka P., Wlazłowski M., Wójcikowska M., Zatorski H., Zwolińska M., Fichna J. Current overview of extrinsic and in-trinsic factors in etiology and progression of inflammatory bowel diseases. Pharmacol. Rep, 2014; Oct;66(5):766-75 doi: 10.1016/j.bbr.2011.03.031.